- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05198206
Pregnant Women With Pulmonary Hypertension in China
Current Status of Diagnosis and Treatment of Pregnancy With Pulmonary Hypertension and Maternal and Infant Outcomes: a Multicentre Retrospective Study in China
Little is known about the status of maternal, obstetric and neonatal complications and the potential predictors of developing heart failure (HF) in the mothers with pulmonary hypertension in China. Eligible samples were screened from January, 2012 to December, 2021. Maternal clinical characteristics and in-and-out hospital outcomes were collected and compared in women with and without pulmonary hypertension.
The main aims of this study are as follows:
- To investigate the perinatal diagnosis and treatment of pregnant women with pulmonary hypertension in China over the past 10 years and the maternal and infant outcomes.
- To explore risk factors that affect the outcome of pregnant women with pulmonary hypertension in mothers and infants.
- To summarise effective risk stratification management protocols and construct standardised strategies for the management of pulmonary hypertension in pregnancy.
- To establish a clinical database, biobank and follow-up cohort for pregnant women with pulmonary hypertension across China.
Přehled studie
Postavení
Detailní popis
Pulmonary hypertension is a malignant disease with a high mortality rate, difficult to diagnose at an early stage and has posed a huge economic burden on patients and society. Pregnancy with pulmonary hypertension is associated with high maternal mortality (25% - 56% ) and a high incidence of fetal complications such as preterm birth (85% - 100%), fetal growth restriction (3% - 33%) and severe outcomes such as fetal/neonatal loss (7% - 13%). A high maternal mortality rate of 30%-56% for pregnancy-related pulmonary hypertension for women and 11-28% for infants has been reported.
However, despite national and international guidelines recommending avoidance of pregnancy, some women with pulmonary hypertension persist in their pregnancies or have unplanned pregnancies, and some pregnant women are diagnosed with pulmonary hypertension only after symptoms such as heart failure have worsened. Although with the development of pulmonary arterial hypertension(PAH)-targeted drugs, the mortality rate for pregnancy-associated PAH has declined but remains relatively high. The high maternal and infant mortality rates and complication rates make it a critical condition that seriously endangers the lives of both mother and child.
Limited data in China reported the outcome, prognosis and management measures of combined pulmonary hypertension in pregnancy, and there is a lack of overall description and analysis of pregnancy with pulmonary hypertension in a multi-centre setting. The current status of high risk factors, efficacy of multidisciplinary consultation and management of maternal and fetal mortality and complications is unclear.
Therefore, the aim of this study was to retrospectively analyse the current status of the management of pregnant women with pulmonary hypertension in a multicenter setting across China, and try to summarise effective risk stratification management protocols and construct standardised strategies for the management of pulmonary hypertension in pregnancy to reduce maternal and infant mortality and adverse events and improve the prognosis of mothers and infants.
Typ studie
Zápis (Očekávaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Wei Huang, Doctor
- Telefonní číslo: 86-23-89011513
- E-mail: weihuangcq@gmail.com
Studijní místa
-
-
Chongqing
-
Chongqing, Chongqing, Čína, 400016
- Nábor
- The First Affiliated Hospital, Chongqing Medical University
-
Kontakt:
- Wei Huang, Doctor
- Telefonní číslo: 86 13638309211
- E-mail: weihuangcq@gmail.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- pregnant women, regardless of age, race
- diagnosed with pulmonary hypertension(PH) before pregnancy or during pregnancy
- diagnosed with PH by right heart catheterization or echocardiography
- diagnostic criteria of right heart catheterization: mean pulmonary artery pressure (mPAP) ≥ 25 mm Hg by right heart catheterization at rest
- diagnostic criteria of echocardiography: pulmonary artery systolic pressure (PASP)≥40 mm Hg
- time: from January 1, 2012 to December 31, 2021
Exclusion Criteria:
- Patients with isolated exercise-induced PH (mean PAP <25 mm Hg at rest and >30 mm Hg at exercise) were excluded.
- pulmonary artery systolic pressure (PASP)<40 mmHg by echocardiography
- mean pulmonary artery pressure (mPAP) < 25 mm Hg by right heart catheterization at rest
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Kohorta
- Časové perspektivy: Retrospektivní
Kohorty a intervence
Skupina / kohorta |
---|
První přidružená nemocnice Chongqing Medical University
|
West China Hospital
|
the First Affiliated Hospital of Xi'an Jiaotong University
|
Guangdong Provincial People's Hospital
|
Xiangya Hospital of Central South University
|
The Second Affiliated Hospital of Harbin Medical University
|
Yan'an Hospital of Kunming City
|
Zhongshan Hospital
|
Gansu Provincial People's Hospital
|
Qilu Hospital of Shandong University
|
Shanxi Provincial Cardiovascular Hospital
|
West China Second Hospital
|
The First Affiliated Hospital of Jilin University
|
Xinqiao Hospital, Army Medical University
|
The First Affiliated Hospital of Guangzhou Medical University
|
the Second Xiangya Hospital of Central South University
|
Shengjing Hospital of China Medical University
|
The Second Affiliated Hospital of Nanchang University
|
Henan Provincial People's Hospital
|
Southwest Medical University Hospital
|
The First Affiliated Hospital of Gannan Medical University
|
University-town Hospital of Chongqing Medical University
|
Chongqing Health Center for Women and Children
|
Kunhua Hospital
|
Changdu People's Hospital of Tibet
|
The Sixth People's Hospital of Chengdu
|
Chongqing Bishan District People's Hospital
|
Sichuan Guangyuan People's Hospital
|
Xinjiang Military Region General Hospital
|
Xinjiang Uygur Autonomous Region People's Hospital
|
The First Affiliated Hospital of Anhui Medical University
|
Yantai Yuhuangding Hospital
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
all-cause maternal mortality
Časové okno: diagnosis of pregnancy to six months postpartum in 2012-2021
|
Investigating the maternal mortality rate from the diagnosis of pregnancy to six months postpartum
|
diagnosis of pregnancy to six months postpartum in 2012-2021
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Maternal incidence of cardiovascular complications
Časové okno: from diagnosis of pregnancy to six months postpartum in 2012-2021
|
heart failure ,arrhythmias, thrombotic events (including valve thrombosis) , aortic dissection and other cardiovascular complications during pregnancy until 6 months postpartum
|
from diagnosis of pregnancy to six months postpartum in 2012-2021
|
the incidence of obstetric events
Časové okno: From delivery to 42 days postpartum
|
the incidence of post-partum hemorrhage, emergency Caesarean section, pre-eclampsia, eclampsia or pregnancy-induced hypertension From delivery to 42 days postpartum
|
From delivery to 42 days postpartum
|
the incidence of fetal events
Časové okno: From delivery to 42 days postpartum
|
prematurity , fetal mortality, early neonatal mortality, intra-uterine growth retardation, low birth weight or low Apgar score from delivery to 42 days postpartum
|
From delivery to 42 days postpartum
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2021XMSB0011013
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Těhotenství, vysoké riziko
-
Array BioPharmaDokončenoAML | Pokročilé a vybrané solidní nádory | High Risk a Very High Risk MDSSpojené státy, Austrálie, Itálie, Španělsko, Francie, Švýcarsko, Spojené království
-
Novartis PharmaceuticalsUkončeno
-
Novartis PharmaceuticalsDokončenoAML a High Risk MDSNěmecko, Itálie, Francie, Holandsko, Spojené státy, Austrálie, Japonsko
-
October University for Modern Sciences and ArtsNáborHigh Frenum AttachmentEgypt
-
Cairo UniversityZatím nenabírámeHigh Frenum Attachment | Gingivální štěp zdarma
-
University Grenoble AlpsDokončenoAnesteziologie | Klinický výkon | Pozitivní komunikace | High Fidelity simulaceFrancie
-
T.C. Dumlupınar ÜniversitesiDokončenoHigh Frenum Attachment
-
University Hospital, Basel, SwitzerlandNáborTriage Risk StratificationŠvýcarsko
-
University Hospital, Basel, SwitzerlandDokončenoTriage Risk StratificationŠvýcarsko
-
Maha Mahmoud AhmedZatím nenabírámeHigh Flow nosní terapie